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MYCN amplification drives one in six cases of neuroblastoma. The supernumerary gene
copies are commonly found on highly rearranged, extrachromosomal circular DNA (ecDNA).
The exact amplicon structure has not been described thus far and the functional relevance of
its rearrangements is unknown. Here, we analyze the MYCN amplicon structure using short-
read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and
Hi-C. This reveals two distinct classes of amplicons which explain the regulatory require-
ments for MYCN overexpression. The first class always co-amplifies a proximal enhancer
driven by the noradrenergic core regulatory circuit (CRC). The second class of MYCN
amplicons is characterized by high structural complexity, lacks key local enhancers, and
instead contains distal chromosomal fragments harboring CRC-driven enhancers. Thus,
ectopic enhancer hijacking can compensate for the loss of local gene regulatory elements and
explains a large component of the structural diversity observed in MYCN amplification.
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Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 5 Experimental and Clinical Research Center (ECRC), Max Delbrück Center for
Molecular Medicine and Charité—Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany. 6 Barcelona Supercomputing Center, Joint BSC-
CRG-IRB Research Program in Computational Biology, Jordi Girona 29, 08034 Barcelona, Spain. 7 German Cancer Consortium (DKTK), partner site Berlin,
and German Cancer Research Center DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. 8 Department of Neurology with Experimental
Neurology, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. 9 Berlin Institute of Health, Anna-Louisa-Karsch-Str. 2, 10178
Berlin, Germany. 10 Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany.
11 Department of Experimental Pediatric Oncology, University Children’s Hospital of Cologne and Center for Molecular Medicine Cologne (CMMC),
University of Cologne, Kerpener Straße 62, 50937 Köln, Germany. 12 Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluís Companys 23,
08010 Barcelona, Spain. 13 Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, 430 East 67th Street, New York, NY 10065, USA.
14These authors contributed equally: Konstantin Helmsauer, Maria Valieva, Salaheddine Ali. 15These authors jointly supervised this work: Stefan Mundlos,
Anton G. Henssen, Richard P. Koche. ✉email: henssenlab@gmail.com; kocher@mskcc.org









Oncogene amplification is a hallmark of cancer genomes. Itleads to excessive proto-oncogene overexpression and is akey driver of oncogenesis. The supernumerary gene
copies come in two forms: (i) self-repeating arrays on a chro-
mosome (homogeneously staining regions, HSR) and (ii) many
individual circular DNA molecules (extrachromosomal DNA,
ecDNA, alias double minute chromosomes, dmin)1. EcDNA can
arise during genome reshuffling events like chromothripsis and
are subsequently amplified2,3. This partially explains why ecDNA
can consist of several coding and non-coding distal parts of one
or more chromosomes4. Over time, amplified DNA acquires
additional internal rearrangements as well as coding mutations,
which can confer adaptive advantages such as resistance to tar-
geted therapy5–7. EcDNA reintegration into chromosomes can
lead to intrachromosomal amplification as HSRs8,9 and act as a
general driver of genome remodeling10. Our knowledge of the
functional relevance of non-coding regions co-amplified on
ecDNA, however, is currently limited.
MYCN amplification is a prototypical example of a cancer-
driving amplification. The developmental transcription factor was
identified as the most commonly amplified gene in a recent
pediatric pan-cancer study11. Its most prominent role is in neu-
roblastoma, a pediatric malignancy of the sympathetic nervous
system. MYCN amplification characterizes one in six cases and
confers dismal prognosis12. In contrast to long-term survival of
more than 80% for non-amplified cases, 5-year overall survival is
as low as 32% for MYCN-amplified neuroblastoma12. In these
cases, MYCN amplification is likely an early driver of neuro-
blastoma formation. Indeed, MYCN overexpression is sufficient
to induce neuroblastic tumor formation in mice13,14. Despite its
central role in neuroblastoma biology, the epigenetic regulation of
MYCN is incompletely understood.
Recently, studies have identified a core regulatory circuit
(CRC) including half a dozen transcription factors that drive a
subset of neuroblastomas with noradrenergic cell identity,
including most MYCN-amplified cases15–18. The epigenetic
landscape around MYCN is less well characterized. In part, this is
due to the structural complexity of MYCN amplicons and diffi-
culties in interpreting epigenomic data in the presence of copy-
number variation. Recent evidence has emerged suggesting that
local enhancers may be required for proto-oncogene expression
on amplicons19. Structural rearrangements can also juxtapose
ectopic enhancers to proto-oncogenes and thereby drive aberrant
expression, a phenomenon known as enhancer hijacking in sev-
eral pediatric tumors20–24. Here, we seek out to identify key
regulatory elements near MYCN in neuroblastoma by integrating
short- and long-read genomic and epigenomic data from neu-
roblastoma cell lines and primary tumors. We investigate the
activity of regulatory elements in the context of MYCN amplifi-
cation and characterize the relationship between amplicon
structure and epigenetic regulation. This reveals the retention of
local CRC-driven enhancers on the MYCN amplicon in the
majority of cases. When such local elements are not co-amplified,
however, amplicons are structurally complex and distal elements
are combined to form novel gene-regulatory neighborhoods.
Results
Defining the local enhancer landscape of MYCN. Acetylation at
the 27th lysine residue of the histone H3 protein (H3K27ac)
characterizes active chromatin at promoters and enhancers25. In
order to identify candidate active regulatory elements near
MYCN, we examined public H3K27ac chromatin immunopreci-
pitation and sequencing (ChIP-seq) and RNA sequencing (RNA-
seq) data from 25 neuroblastoma cell lines15. ChIP-seq data for
amplified genomic regions are characterized by a very low signal-
to-noise ratio, which has complicated their interpretation in the
past16. We therefore focused our analysis on 12 cell lines lacking
MYCN amplifications but expressing MYCN at different levels,
allowing for the identification of MYCN-driving enhancers in
neuroblastoma. Comparison of composite H3K27ac signals of
MYCN-expressing vs. non-expressing cell lines identified at least
five putative enhancer elements (e1–e5) that were exclusively
present in the vicinity of MYCN in cells expressing MYCN, thus
likely contributing to MYCN regulation (Fig. 1 and Supplemen-
tary Fig. 1a). Consistent with differential RNA expression, a
strong differential H3K27ac peak was identified spanning the
























































































Fig. 1 Five enhancers are specifically found in MYCN-expressing neuroblastoma cells. a H3K27ac ChIP-seq fold change over input (left) and size-factor
normalizedMYCN expression as determined from RNA-seq for 12 non-MYCN-amplified neuroblastoma cell lines. b Aggregated H3K27ac signal of MYCN-
expressing compared to non-expressing cells (top, black; MYCNp,MYCN promoter; e1–e5,MYCN-specific enhancers). PHOX2B, GATA3, and HAND2 core
regulatory circuit transcription factor ChIP-seq in an MYCN-expressing neuroblastoma cell line (green, CLB-GA). Source data are provided as a Source
Data file.
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enhancers were not active in developmental precursor cells such
as embryonic stem cells, neuroectodermal cells, neural crest cells,
or fetal adrenal cells (Supplementary Fig. 1b), suggesting these
enhancers were specific for later stages of sympathetic nervous
system development or neuroblastoma. Transcription factor
ChIP-seq in MYCN-expressing cells confirmed that four of the
enhancers (e1, e2, e4, and e5) were bound by each of three
noradrenergic neuroblastoma core regulatory circuit transcription
factors (PHOX2B, HAND2, GATA3; Fig. 1b). All but enhancer e3
harbored binding motifs for the remaining members of the CRC
(ISL1, TBX2, ASCL1; Supplementary Fig. 1c) for which ChIP-seq
data were unavailable. Additionally, all enhancers contained
binding motifs for TEAD4, a transcription factor implicated in a
positive feedback loop with MYCN in MYCN-amplified neuro-
blastoma26. Two of the enhancers (e1 and e2) also harbored
canonical E-boxes, suggesting binding of MYCN at its own
enhancers (Supplementary Fig. 1c). Taken together, a common
set of CRC-driven enhancers is found uniquely in MYCN-
expressing neuroblastoma cells, indicating that MYCN expression
is regulated by the CRC.
Enhancer selection explains MYCN amplicon boundaries.
MYCN is expressed at the highest levels in neuroblastomas har-
boring MYCN amplifications, with a strong effect of genomic
copy number on expression levels (Supplementary Fig. 1d, e). It is
unclear, however, to what extent enhancers are required for
sustained MYCN expression on MYCN-containing amplicons. To
address this, we mapped amplified genomic regions in a meta-
dataset of copy-number variation in 240 MYCN-amplified neu-
roblastomas27. This revealed an asymmetric pattern of MYCN
amplification (Fig. 2a and Supplementary Fig. 2). Intriguingly, a
290 kb region downstream of MYCN was co-amplified in more
than 90% of neuroblastomas, suggesting that MYCN amplicon
boundaries were not randomly distributed, which is in line with
recent reports using a smaller tumor cohort19. Notably, the
consensus amplicon boundaries did not overlap with common
fragile sites (Supplementary Fig. 2g), challenging a previous
association found in 24 neuroblastoma cell lines and tumors28.
Regions of increased chromosomal instability alone are therefore
unlikely to explain amplicon boundaries. Strikingly, several
MYCN-specific enhancers were found to be commonly co-
amplified (Fig. 2b). The distal MYCN-specific CRC-driven
enhancer, e4, was part of the consensus amplicon region in
90% of cases. Randomizing amplicon boundaries around MYCN
showed that e4 co-amplification was significantly enriched on
MYCN amplicons (empirical P= 0.0003). Co-amplification fre-
quency quickly dropped downstream of e4, suggesting that
MYCN-specific, CRC-driven enhancers are a determinant of
MYCN amplicon structure and may be required for MYCN
expression, even in the context of high-level amplification.
Considering that MYCN is amplified in many pediatric cancer
entities that differ in chromatin landscape, we hypothesized that
MYCN amplicon structure should also differ between cancer
entities. To test this, we inspected the amplicon architecture in a
cohort of sonic hedgehog-driven medulloblastomas (SHH-MB)
and Group 4 medulloblastomas (GROUP4-MB)29, which often
harbor MYCN amplifications and are commonly thought to
originate from different precursor cell types30. In line with our
model of tissue-specific enhancer co-amplification, MYCN
amplicon structure differed between medulloblastomas and
neuroblastomas (Supplementary Fig. 3a). MYCN amplicon
distributions also differed between SHH-MB and GROUP4-MB
(Supplementary Fig. 3b). A SHH-MB-specific super-enhancer
(SE) > 350 kb downstream of MYCN was co-amplified in 8/9
cases, indicating selection. GROUP4-MB lack MYCN-driving SEs
and are characterized by several enhancers close to MYCN. At
least one of these local enhancers was co-amplified in 11/12 cases.
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Fig. 2 Local enhancer e4 is significantly co-amplified with MYCN. a Co-amplification frequency of the immediate MYCN neighborhood measured using
copy-number profiles from 240 MYCN-amplified neuroblastomas (solid line) compared to the expected co-amplification frequencies for randomized
MYCN-containing amplicons (dashed line). b Upset plot showing the co-amplification patterns of all five MYCN-specific local enhancers identified in
neuroblastoma. c Enrichment for co-amplification with MYCN of genomic regions on 2p (red, co-amplification more frequent than expected by chance;
blue, co-amplification less frequent than expected by chance). Source data are provided as a Source Data file.
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amplicon structure and may be required for MYCN expression in
various tumor entities.
Distal super-enhancer co-amplification with MYCN. We and
others have previously described chimeric MYCN amplicons10
containing distal chromosomal fragments. We therefore system-
atically inspected MYCN-distal regions on chromosome 2 for
signs of co-amplification. Distinct regions were statistically enri-
ched for co-amplification with MYCN (Fig. 2c). In line with
previous reports31, significant co-amplification of 19 protein-
coding genes, including known neuroblastoma drivers such as
ODC1, GREB1, and ALK occurred in MYCN-amplified neuro-
blastoma. Notably, co-amplification of distal CRC-driven SEs
occurred in 23.3% of samples. Seven specific CRC-driven SEs
were significantly co-amplified more often than expected by
chance. Most of these SEs were found in gene-rich regions,
making it difficult to discern whether genes or regulatory ele-
ments were driving co-amplification. One significantly co-
amplified CRC-driven SE, however, was found in a gene-poor
region in 2p25.2, where most co-amplified segments did not
overlap protein-coding genes (Fig. 2c). This led us to ask whether
hijacking of such distal regulatory elements could explain co-
amplification with MYCN.
Enhancers remain functional on MYCN amplicons. Based on
our amplicon boundary analysis, two classes of MYCN amplicons
could be distinguished in neuroblastoma: (i) amplicons contain-
ing local MYCN-specific enhancers, including e4 (here referred to
as class I amplicons; Fig. 3a) and (ii) amplicons lacking local
MYCN-specific enhancers, and at least lacking e4 (referred to as
class II amplicons; Fig. 3b). To determine whether co-amplified
enhancers were active, we acquired genomic (long- and short-
read whole-genome sequencing) and epigenomic (Assay for
Transposase-Accessible Chromatin using sequencing, ATAC-seq,
and mono-methylation at the fourth lysine residue of the histone
H3, H3K4me1, and H3K27ac ChIP-seq) data for two neuro-
blastoma cell lines with class I amplicons (Kelly and NGP) and
two neuroblastoma cell lines with class II amplicons (IMR-5/75
and CHP-212). Notably, H3K27ac signal-to-noise ratio was lower
on MYCN amplicons than in non-amplified regions. While the
fraction of reads in peaks was similar across amplicons and
randomly drawn regions, we observed more peaks on the
amplicon than for non-amplified regions (Supplementary Fig. 4).
These peaks were characterized by a lower relative signal com-
pared to the amplicon background signal, indicating a larger
variety of active regulatory regions on differentMYCN amplicons.
Using nanopore long-read-based de novo assembly, we recon-
structed theMYCN neighborhood, confirming thatMYCN and e4
were not only co-amplified in class I amplicons, but also lacked
large rearrangements, which could preclude enhancer–promoter
interaction (Supplementary Figs. 5 and 6). Enhancer e4 was
characterized by increased chromatin accessibility and active
enhancer histone marks as determined by ATAC-seq, H3K4me1,
and H3K27ac ChIP-seq (Fig. 3c). Importantly, 4C chromatin
conformation capture analysis showed that e4 spatially interacted
with the MYCN promoter on the amplicon (Fig. 3c). Thus, e4
presents as a functional enhancer and appears to contribute to
MYCN expression, even in the context of class I MYCN
amplification.
Enhancer hijacking compensates for local enhancer loss. In
contrast to class I amplicons, class II amplicons lacked key local
enhancers and nevertheless expressed relatively high levels of
MYCN per gene copy, raising the possibility of alternative routes
of MYCN regulation (Supplementary Fig. 7). The lack of a strong
local regulatory element on class II amplicons and our observa-
tion of frequent co-amplification of distal SE (Fig. 2c) led us to
hypothesize that ectopic enhancers might be recruited to enable
MYCN expression in class II amplicons. In agreement with our
hypothesis, primary neuroblastomas with class II amplicons were
more likely to harbor complex amplifications containing more
than one amplified fragment in the genome (66.7% vs. 35.7%,
Fisher’s exact test P= 0.003; Fig. 3e). In this largely array-based
dataset, we cannot exclude fragments that are not structurally
fused to the MYCN locus. However, it is unlikely that highly
amplified loci have very similar copy number if they are not part
of a common amplicon. We therefore filtered for fragments with
highly similar copy number as MYCN (log ratio difference ≤0.1)
and again found increased amplicon complexity for class II (class
II 36.0% vs. class I 11.6%, Fisher’s exact test P= 0.003). All but
one class II amplicon co-amplified at least one CRC-driven
enhancer element distal of MYCN. Some of these enhancers were
recurrently found on class II amplicons, including an enhancer
1.2 Mb downstream of MYCN that was co-amplified in 20.8% (5/
24) of MYCN-amplified neuroblastomas, 2.1-fold higher than
expected for randomized amplicons that include MYCN but not
e4 (Fig. 3f). Thus, class II MYCN amplicons are characterized by
high structural complexity, allowing for the replacement of local
enhancers through hijacking of distal CRC-driven enhancers.
To determine the structure and epigenetic regulation of class II
amplicons in detail, we inspected long-read-based de novo
assemblies and short-read-based reconstructions of IMR-5/75
and CHP-212 MYCN amplicons. High-throughput chromosome
conformation capture (Hi-C) was performed and validated the
reconstructions, recapitulating the order and orientation of the
joined fragments. IMR-5/75 was characterized by a linear HSR
class II MYCN amplicon, not including e3–e5 (Fig. 3b).
Inspection of the IMR-5/75 MYCN amplicon structure revealed
that the amplicon consisted of six distant genomic regions, which
were joined together to form a large and complex chimeric
amplicon (Fig. 4a–d). One of the fragments was likely included as
a tandem duplication on the amplicon (Supplementary Fig. 8a).
In line with enhancer hijacking, a segment of ALK containing a
large SE, marked by H3K27ac and chromatin accessibility as
measured using ATAC-seq, was juxtaposed with MYCN on the
chimeric amplicon. Similar to e4, this enhancer was bound by
adrenergic CRC factors in non-amplified cells (Supplementary
Fig. 9a). In CHP-212, MYCN is amplified on ecDNA, as
confirmed by fluorescence in situ hybridization (Supplementary
Fig. 10). Both de novo assembly and short-read-based recon-
struction of the amplicon confirmed the circularMYCN amplicon
structure independently (Fig. 4f–h). Similar to IMR-5/75, distal
fragments containing CRC-driven SEs were joined to the MYCN
neighborhood (Fig. 4e, f and Supplementary Fig. 9b).
Neo-topologically associated domains (TADs) form on chi-
meric MYCN amplicons. To analyze the three-dimensional
conformation of circular and linear amplicons we mapped Hi-C
reads to the reconstructed amplicon (Fig. 4c, g). Notably, high-
frequency interactions in the corners of the maps opposite to the
main diagonal confirmed the circularity of CHP-212 amplicon
and tandem duplication-type amplification in IMR-5/75. On a
more local level, Hi-C can be used to characterize TADs, i.e.
regions of increased spatial interaction which contribute to gene
control and arise through chromatin loops anchored at CTCF-
marked insulator elements32. In IMR-5/75 and CHP-212, we
observed insulated TADs as in the rest of the genome, suggesting
that general rules of chromatin topology are retained on ecDNA
and HSRs. Due to the rearrangements in CHP-212, the MYCN
gene became part of a new chromatin domain (neo-TAD) where
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genes, enhancers, and insulators from distal parts of the genome
form a new spatially interacting neighborhood. MYCN itself was
located at the intersection of two smaller sub-TADs. The first
sub-TAD originated from the wild-type genome as an intact unit.
The second sub-TAD resulted from the fusion of theMYCN locus
with another region from a distal part of chromosome 2
(chr2:12.6–12.8 Mb) containing CRC-driven SEs (Fig. 4g and
Supplementary Fig. 9b). The fused segments were part of one
TAD and not separated by a boundary, which enables the
interaction ofMYCN with the ectopic SEs. A similar situation was
observed for the linear amplicon in IMR-5/75, where frequent
contacts between MYCN and SEs from the genomic regions
juxtaposed to MYCN, containing intronic parts of ALK, were
detected using Hi-C (Fig. 4c and Supplementary Figs. 8b and 9a).
Notably, hijacked SEs covered 46% and 44% of the neo-TAD for
IMR-5/75 and CHP-212, respectively. In both cell lines, addi-
tional fragments of chromosome 2 were fused to the SE-
containing region. These contained neo-TAD boundaries as
determined by Hi-C (Fig. 4d, g). All neo-TAD boundaries were
marked by CTCF ChIP-seq peaks, with canonical
forward–reverse motif orientations in IMR-5/75 (Supplementary
Fig. 9a). In CHP-212, no unambiguous CTCF motif orientations
at the downstream neo-TAD border were identified (Supple-
mentary Fig. 9b). In both cases, however, the new insulators
originated from genomic locations other than the MYCN frag-























































































































































0 5 10 15
Class I (with e4)
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Fig. 3 Two classes of MYCN amplicons can be identified in neuroblastoma. Schematic representation of class I (a) and class II (b) MYCN amplicons.
c Copy-number profile (black), ATAC-seq (orange), H3K27ac ChIP-seq (purple), H3K4me1 ChIP-seq (pink), and 4C (MYCN promoter as the viewpoint;
green) for two neuroblastoma cell lines with class I amplicons, co-amplifying the e4. d Copy-number profile (black), ATAC-seq (orange), H3K27ac ChIP-
seq (purple), H3K4me1 ChIP-seq (pink), and virtual 4C (MYCN locus as the viewpoint; green) for two neuroblastoma cell lines class II amplicons, not co-
amplifying e4. e Number of non-contiguous amplified fragments in class I samples (N= 216) vs. class II samples (N= 24). f Amplicon boundary frequency
relative to gene and enhancer positions in class I vs. class II amplicons compared to random amplicon boundary frequencies. Source data are provided as a
Source Data file.
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observed TAD structures, weaker off-diagonal interactions were
visible, suggesting a heterogeneous group of structurally different
variants of the original amplicon. Nevertheless, the TAD struc-
ture, boundaries, and loops were clearly visible on the recon-
structed Hi-C map (Fig. 4c). Thus, hijacking of ectopic enhancers
and insulators can compensate for the loss of endogenous reg-
ulatory elements on intra- and extrachromosomal circular class II
MYCN amplicons via the formation of neo-TADs, which may








































































































































































































































































































Fig. 4 Reconstruction and epigenetic markup of class II MYCN amplicons. a, e Short-read-based reconstruction and epigenomic characterization of the
MYCN amplicon in IMR-5/75 (a) and CHP-212 (e) cells. Top to bottom: Hi-C map (color indicating Knight–Ruiz normalized read counts in 25 kb bins),
virtual 4C (MYCN viewpoint, v4C), CTCF ChIP-seq, H3K27Ac ChIP-seq, Amplicon reconstruction, copy-number profile, super-enhancer locations (yellow),
gene positions (blue). b, f Schematic representation of the class II amplicon described in a, e, showing ectopic enhancers and insulator reshuffling leading
to locally disrupted regulatory neighborhoods on the HSR in IMR-5/75 (b) and on ecDNA in CHP-212 (f). c, g Alignment of Hi-C reads to the reconstructed
MYCN amplicon in IMR-5/75 (c) and CHP-212 (g) and positions of genes, local MYCN enhancers and CRC-driven super-enhancers on the amplicon. d, h
Mapping of the long-read sequencing-based de novo assembly of the MYCN amplicon in IMR-5/75 (d) and CHP-212 (h) on chromosome 2. Source data
are provided as a Source Data file.
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Nanopore sequencing characterizes amplicon methylation. In
addition to allowing the alignment-free de novo assembly of the
MYCN amplicon in several samples (Fig. 4b–d, f–h and Supple-
mentary Figs. 5 and 6), nanopore sequencing also allows for the
direct measurement of DNA methylation without the need for
bisulfite conversion (Fig. 5a)33. While DNA methylation at reg-
ulatory elements is often associated with repression, a trough in
DNA methylation may indicate a transcription factor-binding
event, a poised or active gene-regulatory element, or a CTCF-
occupied insulator element (Fig. 5b). In theory, nanopore
sequencing and assembly might allow for the simultaneous
inference of both structure and regulatory landscape (Fig. 5b).
Prior to evaluating the MYCN amplicons, the DNA methylation
landscape of highly expressed and inactive genes demonstrated
the expected distribution of decreased methylation at active
promoters and increased methylation within active gene bodies
(Fig. 5c). In order to assess the DNA methylation status of
putative regulatory elements near MYCN, we first used the
amplicon-enriched ATAC-seq peaks to classify relevant motif
signatures (Fig. 5d). While MYCN was surrounded by the
expected CRC-driven regulatory elements at the overlapping core
enhancers as well as some CTCF sites, both their number and
location varied, indicating sample-specific sites of regulation.
Indeed, DNA methylation decreased in accordance with sites
specific to a given sample (Fig. 5e), opening up the possibility of
using these data to infer regulatory elements in patient samples,
when no orthogonal epigenomic data are available.
Class II amplicons clinically phenocopy class I amplicons.
MYCN-amplified neuroblastoma is characterized by significant
clinical heterogeneity, which cannot entirely be explained by
genetic differences. Whether the structure of theMYCN amplicon
itself could account for some of this variation is currently
unknown. In line with previous reports31, higher counts of
amplified fragments were associated with a more malignant
clinical phenotype (Fig. 6a). Co-amplification of ODC1, a gene
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Fig. 5 Nanopore sequencing characterizes DNA methylation on MYCN amplicons. a Schematic of experimental approach. b Schematic representation of
how nanopore sequencing facilitates de novo amplicon assembly and can be used to simultaneously to detect regulatory elements through DNA
methylation analysis. c Composite DNA methylation signal detected using nanopore sequencing over genes expressed at high (HighExpr) vs. low levels
(LowExpr). d Motif analysis based on accessibility in regulatory elements co-amplified on MYCN amplicons (unadjusted P values from one-sided binomial
test against nucleotide composition-matched background sequences). e Amplicon-specific methylation pattern detected in three neuroblastoma cell lines
(Kelly, IMR-5/75, CHP-212) using nanopore sequencing-based DNA methylation analysis.
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240) of MYCN-amplified neuroblastomas (Fig. 2c), defined an
ultra-high-risk genetic subgroup of MYCN-amplified neuro-
blastoma (hazard ratio (HR) 2.3 (1.4–3.7), log-rank test P=
0.001; Fig. 6b). Similarly, ALK co-amplification, present in 5%
(12/240) of MYCN-amplified tumors, was also associated with
adverse clinical outcome (HR 1.8 (0.94–3.4), log-rank test P=
0.073; Fig. 6c). In contrast, differences in the MYCN amplicon
enhancer structure, i.e. class I vs. class II amplification, did not
confer prognostic differences (HR 1.3 (0.78–2.1), log-rank test
P= 0.34; Fig. 6d). We therefore conclude that chimeric co-
amplification of proto-oncogenes partly explains the malignant
phenotype of neuroblastomas with complex MYCN amplicons,
whereas enhancer hijacking in class II amplicons does not change
clinical behavior, fully phenocopying class I MYCN amplicons.
Discussion
Here, we show that neuroblastoma-specific CRC-driven enhan-
cers contribute to MYCN amplicon structure in neuroblastoma
and retain the classic features of active enhancers after genomic
amplification. While most MYCN amplicons contain local
enhancers, ectopic enhancers are regularly incorporated into
chimeric amplicons lacking local enhancers, leading to enhancer
hijacking (Fig. 7).
A large subset of neuroblastomas was recently found to be
driven by a small set of transcription factors that form a self-
sustaining CRC, defined by their high expression and presence of
super-enhancers15–18. The extent to whichMYCN itself is directly
regulated by CRC factors was previously unclear, complicated by
the challenge of interpreting epigenomic data on amplicons16.
Our results provide empiric evidence that MYCN is driven by
CRC factors, even in the context of MYCN amplification. This
could mechanistically explain the previous observation that
genetic depletion of CRC factors represses MYCN expression
even in MYCN-amplified cells16. The finding that ectopic
enhancers driven by the CRC are juxtaposed to MYCN on
amplicons that lack local enhancers further strengthens the
relevance of the CRC in MYCN regulation.
In line with our observation of local enhancer co-amplification,
Morton et al.19 recently described that local enhancers are sig-
nificantly co-amplified with other proto-oncogenes in other cancer
entities. They showed that experimentally interfering with local
EGFR enhancers in EGFR-amplified glioblastoma impaired onco-
gene expression and cell viability in EGFR-amplified as well as non-
amplified cases. Consistent with our findings, the authors identified
a region overlapping e4 that was significantly co-amplified in
MYCN-amplified neuroblastomas, corresponding to class I ampli-
cons observed in our cohort. In contrast to Morton et al.19, who
suggest that the inclusion of local enhancers is necessary for proto-
oncogene expression on amplicons, we show that exceptions to this
rule occur in a significant subset of MYCN-amplified neuro-



































































































Fig. 6 Class II amplicons clinically phenocopy class I amplicons. Kaplan Meier survival analysis of patients with MYCN-amplified neuroblastoma,
comparing single-fragment vs. multi-fragment amplification (a), co-amplification of ODC1 vs. no co-amplification (b), co-amplification of ALK vs. no co-
amplification (c), and class I amplicons vs. class II amplicons (d; N= 236 MYCN-amplified neuroblastomas; P value based on two-sided log-rank test).






















Fig. 7 Enhancer co-amplification determinesMYCN amplicon patterns. In most cases,MYCN and its local gene-regulatory neighborhood including a CRC-
driven super-enhancer is amplified (Class I). If the local neighborhood is not co-amplified, amplicons are more complex and recruit distal gene-regulatory
elements (Class II).
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complex chimeric structure enable the reshuffling of ectopic
enhancers and insulators to form neo-TADs that can compensate
for disrupted local neighborhoods through enhancer hijacking.
More generally, we show that TADs also form on ecDNA, in
parallel with recent findings by Wu et al.34. We extend this
observation to HSRs, which form extremely expanded stretches of
chromatin in interphase nuclei and lose chromosomal territori-
ality35. Gene activation by enhancer adoption requires the fusion
of distant DNA fragments and the formation of new chromatin
domains, called neo-TADs36. In some cases, this fusion requires a
convergent directionality of CTCF sites in order to form a new
boundary and drive aberrant gene expression37. This has been
explained by a model of blocked loop extrusion at
forward–reverse oriented CTCF sites32. We found convergent
CTCF for the neo-TAD in IMR-5/75 but not necessarily for the
one in CHP-212. However, non-convergent CTCF sites have been
consistently reported before and characterize at least one in ten
CTCF-mediated chromatin loops in the wild-type genome38,39.
Although the exact underpinnings are not yet clear, CTCF con-
vergence is likely not required in some genomic contexts, which
could be the case in CHP-212 and other ecDNA amplicons.
Reconstruction of amplicons has previously relied on combining
structural breakpoint coordinates to infer the underlying structure.
This regularly resulted in ambiguous amplicon reconstructions,
which had to be addressed by secondary data such as chromium
linked reads or optical mapping4,6,34. We demonstrate the feasibility
of long-read de novo assembly for the reconstruction of amplified
genomic neighborhoods. De novo assembly was able to reconstruct
entire ecDNA molecules and confirm the tandem duplicating nat-
ure of HSRs. Integrating de novo assembly with methylation data
from nanopore sequencing reads will likely benefit further studies of
other proto-oncogene-containing amplicons by enabling the char-
acterization of the interplay between structure and regulation in
highly rearranged cancer genomes.
Functional studies have shown that both ODC1 and ALK are
highly relevant in neuroblastoma40,41. Co-amplification with
MYCN has been reported before31, but to our knowledge the
clinical relevance of co-amplification had not been determined so
far. Similar to our previous observations of PTP4A2 co-
amplification on chimeric ecDNA10, we demonstrate here that
proto-oncogenes reside side-by-side on the same ecDNAs,
sometimes even sharing the same regulatory neighborhood. It is
tempting to speculate that this structural coupling of genes could
confer MYCN-independent but MYCN-amplicon-specific, col-
lateral therapeutic vulnerabilities in MYCN-amplified tumors.
We conclude that the structure of genomic amplifications can
be explained by a selective pressure to amplify oncogenes together
with suitable non-coding regulatory elements. CRC-driven
enhancers are required for successful MYCN amplification and
remain functional throughout this process. Even though the
majority of amplicons contain endogenous enhancers, these can
be functionally replaced by ectopic CRC-driven enhancers that
are juxtaposed to the oncogene through complex chimeric
amplicon formation. We envision that our findings also extend to
oncogene amplifications in other cancers and will help identify
functionally relevant loci among the diverse array of complex
aberrations that drive cancer.
Methods
Cell lines. Neuroblastoma cell lines were a gift from F. Speleman (Cancer Research
Institute Ghent, Ghent, Belgium; NGP), F. Westermann (German Cancer Research
Center, Heidelberg, Germany; IMR-5/75), obtained from the German Collection of
Microorganisms and Cell Cultures (DSMZ GmbH, Braunschweig, Germany;
Kelly), or obtained from the American Type Culture Collection (ATCC, Manassas,
VA; CHP-212). Cell line identity was verified by STR genotyping (Genetica DNA
Laboratories, Burlington, NC and IDEXX BioResearch, Westbrook, ME) and
absence of Mycoplasma sp. contamination was determined with a Lonza
MycoAlert system (Lonza Group Ltd, Basel, CH). All cell lines were cultured in
RPMI-1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA) with 1%
Penicillin/Streptomycin and 10% FCS.
RNA-seq. Public RNA-seq data were downloaded from Gene Expression Omnibus
(GSE90683)15. FASTQ files were quality controlled (FASTQC 0.11.8) and adapters
were trimmed (BBMap 38.58). We mapped reads to GRCh37 (STAR 2.7.1 (ref. 42)
with default parameters), counted them per gene (Ensembl release 75, feature-
Counts from Subread package 1.6.4 (ref. 43)), and normalized for library size and
composition (sizeFactors from DESeq2 1.22.2 (ref. 44)).
ChIP-seq. For the cell lines CHP-212, NGP, and Kelly, 5–10 × 106 cells were
digested with Trypsin–EDTA 0.05% (Gibco) for 10 min at 37 °C. The cells were
mixed with 10% FCS–PBS, and a single-cell suspension was obtained using a 40-
µm cell strainer. After centrifugation, cells were resuspended in 10% FCS–PBS
again and fixed in 1% paraformaldehyde (PFA) for 10 min at room temperature.
The reaction was quenched with 2.5 M glycine (Merck) on ice and centrifuged at
400g for 8 min. We resuspended cell pellets in lysis buffer (50 mM Tris, pH 7.5;
150 mM NaCl; 5 mM EDTA; 0.5% NP-40; 1.15% Triton X-100; protease inhibitors
(Roche), 5 mM Na-butarate), and nuclei were pelleted again by centrifugation at
750g for 5 min. For sonication, nuclei were resuspended in sonication buffer
(10 mM Tris–HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% Na-
deoxycholate; 0.5% N-lauroylsarcosine; protease inhibitors (Roche complete),
5 mM Na-butarate). Chromatin was sheared using a Diagenode Bioruptor (35–40
cycles with a 30 s on/off pulse and HI power mode) until reaching a fragment size
of 200–500 base pairs (bp). Lysates were clarified from sonicated nuclei, and
protein–DNA complexes were immunoprecipitated overnight at 4 °C with the
respective antibody. A total of 10–15 μg chromatin was used for each replicate of
histone ChIP and 20–25 µg of transcription factor ChIP. For the immunopreci-
pitation45 in 1200 µl precipitation buffer (10 mM Tris–HCl, pH 8.0; 100 mM NaCl;
1 mM EDTA; 0.5 mM EGTA; 0.1% Na-deoxycholate; 0.5% N-lauroylsarcosine;
protease inhibitors (Roche complete), 5 mM Na-butarate, 1% Triton X-100), Anti-
H3K27ac (Diagenode c15410174; lot A7071-001P; dilution 1:500), anti-H3K4m1
(Abcam; ab8895; lot GR141677-1; dilution 1:1200), anti-RAD21 (Abcam; ab992;
lot GR221348-8; dilution 1:150) and anti-CTCF (Active Motif; 613111; lot
34614003; dilution 1:150) antibodies were used. Sequencing libraries were prepared
using standard Nextera adapters (Illumina) according to the supplier’s recom-
mendations. Twenty-five million reads per sample were sequenced on a HiSeq
4000 sequencer (Illumina) in 75 bp single read mode.
Additional public ChIP-seq FASTQ files were downloaded from Gene
Expression Omnibus (GSE18927, GSE90683, GSE24447, and GSE28874)15,46 and
from ArrayExpress (E-MTAB-6570)17. FASTQ files were quality controlled
(FASTQC 0.11.8) and adapters were trimmed (BBMap 38.58). Reads were then
aligned to hg19 (BWA-MEM 0.7.15 (ref. 47) with default parameters) and duplicate
reads removed (Picard 2.20.4). We generated BigWig tracks by extending reads to
200 bp for single-end libraries and extending to fragment size for paired-end
libraries, filtering by ENCODE DAC blacklist and normalizing to counts per
million in 10 bp bins (deepTools 3.3.0 (ref. 48)). Peaks were called using MACS2
(2.1.2)49 with default parameters. Super-enhancers were called for H3K27ac data
using LILY15 (https://github.com/BoevaLab/LILY) with default parameters. ChIP-
seq data were quality controlled using RSC and NSC (Phantompeakqualtools
1.2.1). CTCF motifs within CTCF ChIP-seq peaks were identified using
JASPAR2018 (ref. 50) and the TFBSTools (1.20.0)51 function matchPWM with
min.score= “75%”. Copy-number ratio was estimated by binning ChIP-seq input
reads (primary alignments of mapping quality 20 or higher) in 1 kb bins, correcting
for GC content, normalization, and segmentation using QDNAseq (1.22.0)52.
ATAC-seq. ATAC-seq samples were processed as reported in Buenrostro et al.53
with some adaptations: After a treatment of 5–10 × 106 cells with Trypsin–EDTA
0.05% (Gibco) for 10 min at 37 °C, a 40-µm cell strainer was used to obtain a
single-cell suspension. 5 × 105 cells were washed with cold 1× PBS and lysed with
freshly prepared lysis buffer (10 mM Tris-Cl pH 7.4, 10 mM NaCl, 3 mM MgCl2,
0.1% (v/v) Igepal CA-630) by pipetting six times up and down and a subsequent
incubation on ice for 1 min. After a centrifugation at 500g for 5 min at 4 °C the
pellet was resuspended with gentle mixing in transposition reaction mix (25 µl 2×
TD, 2.5 µl TDE1 and 22.5 µl H2O, Illumina). Immediately after the transposition
reaction, the DNA was purified using a MinElute PCR Purification Kit (Qiagen).
The transposed DNA was amplified using a Nextera PCR Kit (Illumina) according
to the supplier’s recommendation. The maximum number of cycles was deter-
mined with qPCR to reduce PCR bias. For sequencing, libraries were generated
using Illumina/Nextera adapters and size selected (100–1000 bp) with AMPure
Beads (Beckman Coulter). Approximately 100 million 75 bp paired-end reads were
acquired per sample on the HiSeq 4000 system (Illumina). Additional public
ATAC-seq FASTQ files were downloaded from Gene Expression Omnibus
(GSE80154)54. Adapter trimming, alignment, and duplicate removal as for ChIP-
seq. We generated BigWig tracks by extending paired-end reads to fragment size,
filtering by the ENCODE DAC blacklist and normalizing to counts per million in
10 bp bins (deepTools 3.3.0 (ref. 48)). Peaks were called using MACS2 (2.1.2)49 with
default parameters.
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Hi-C. 3C libraries for Hi-C and 4C were prepared from confluent neuroblastoma
cells according to the cell culture section above. Hi-C experiments were performed
as duplicates. 5–10 × 106 cells were washed twice with PBS and digested with
Trypsin–EDTA 0.05% (Gibco) for 10 min at 37 °C. A 40-µm cell strainer was used
to obtain single cells. The cell suspension was pelleted at 300g for 5 min and
resuspended with cold 10% FCS. Subsequently, the cells were fixed by adding an
equal volume of 4% formaldehyde (Sigma-Aldrich). The suspension was mixed for
10 min while shaking at room temperature in 50 ml tubes. Exactly after 10 min the
fixation was quenched with 500 µl 1.425 M glycine (Merck) on ice. The suspension
was pelleted at 400g for 8 min and resuspended in cold lysis buffer (50 mM Tris,
pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.5% NP-40; 1.15% Triton X-100; protease
inhibitors (Roche)). After a washing step with cold 1× PBS and centrifugation at
750g for 5 min, the pellet was washed with 1× DpnII buffer (NEB) and resuspended
in 50 µl 0.5% SDS and incubated for 10 min at 62 °C. After that 145 µl water and 25
µl 10% Triton (Sigma) was added to quench the SDS followed by a incubation at
37 °C for 30 min. For the restriction enzyme digestion, 25 µl DpnII buffer and 100
U DpnII was added. The digestion reaction was incubated for 2 h at 37 °C, after 1 h
another 10 U were added and then heat inactivated at 65 °C for 20 min.
The digested sticky ends were filled up with 10 mM dNTPs (without dATP) and
0.4 mM biotin-14-dATP (Life Technologies) and 40 U DNA Pol I, Large Klenow
(NEB) at 37 °C for 90 min. Biotinylated blunt ends were then ligated using a
ligation reaction (663 µl water, 120 µl 10× NEB T4 DNA ligase buffer (NEB), 100 µl
10% Triton X-100 (Sigma), 12 µl 10 mg/ml BSA, and 2400 U of T4 DNA ligase
(NEB)) overnight at 16 °C with slow rotation.
For the 3C library preparation, DNA was sheared using a Covaris sonicator
(duty cycle: 10%; intensity: 5; cycles per burst: 200; time: six cycles of 60 s each; set
mode: frequency sweeping; temperature: 4–7 °C). After sonication, religated DNA
was pulled down using 150 µl of 10 mg/ml Dynabeads Streptavidin T1 beads
(Thermo Fisher) according to the supplier’s recommendation. Sheared and pulled
down DNA was treated using a 100 µl end-repair reaction (25 mM dNTPs, 50 U
NEB PNK T4 Enzyme, 12 U NEB T4 DNA polymerase, 5 U NEB DNA pol I, Large
(Klenow) Fragment, 10× NEB T4 DNA ligase buffer with 10 mM ATP) and
incubated for 30 min at 37 °C.
Universal sequencing adaptor were added using the NEBnext Ultra DNA
Library Kit (NEB) according to the supplier’s recommendation. The PCR cycle
number was adjusted to 4–12 based on the initial DNA concentration. The final
libraries were purified using AMPure Beads (Beckman Coulter) and samples were
sequenced with Ilumina Hi-Seq technology according to the standard protocols
and 75 bp (shallow CHP-212 Hi-C, deep IMR-5/75) and 150 bp (shallow IMR-5/75
Hi-C) paired-end mode. Around 100 million reads were generated per IMR-5/75
replicate (deep IMR-5/75 Hi-C) and around 5–25 million reads per replicate were
generated for shallow CHP-212 and shallow IMR-5/75 Hi-C.
FASTQ files were processed using the Juicer pipeline v1.5.6, CPU version55,
which was set up with BWA v0.7.17 (ref. 47) to map short reads to reference
genome hg19, from which haplotype sequences were removed and to which the
sequence of Epstein–Stein–Barr Virus (NC_007605.1) was added. Replicates were
processed individually. Mapped and filtered reads were merged afterwards. A
threshold of MAPQ ≥ 30 was applied for the generation of Hi-C maps with Juicer
tools v1.7.5 (ref. 55). Knight–Ruiz normalization was used for Hi-C maps38,56. In
cases with copy-number variation within the amplicon, we visually compared
unnormalized, Knight–Ruiz-normalized and local iterative correction-
normalized57 maps to confirm the robustness of our conclusions across different
normalization approaches (Supplementary Fig. 8). Virtual 4C signal for the MYCN
locus was generated by the mean Knight–Ruiz-normalized Hi-C signal across three
5 kb bins (chr2: 16,075,000–16,090,000).
4C-seq. For 4C-seq libraries, a starting material of 5 × 106–1 × 107 cells were used.
The fixation and lysis were performed as described in the “Hi-C” section. After the
first digestion with DpnII (NEB), sticky ends were religated in a 50 ml falcon tube
(700 µl 10 ligation buffer (Fermentas), 7 ml H2O, 50 U T4 DNA ligase (Thermo);
overnight at 16 °C) and DNA de-cross linked and cleaned as described in the “HiC”
section. Subsequently, a second digestion (150 µl sample, 50 µl 10× Csp6I buffer
(Thermo), 60 U Csp6I (Thermo) 295 µl H2O; overnight at 37 °C) and another re-
ligation was performed. For the MYCN promoter viewpoint, DNA was purified
using a PCR clean up Kit (Qiagen) and 1.6 µg DNA was amplified by PCR (Primer
1 5′-GCAGAATCGCCTCCG-3′, Primer 2 5′-CCTGGCTCTGCTTCCTAG-3′).
For the library reaction, primers were modified with TruSeq adapters (Illumina):
Adapter1 5′-CTACACGACGCTCTTCCGATCT-3′ and Adapter2 5′-CAGAC
GTGTGCTCTTCCGATCT-3′. The input of a single 4C PCR reaction was between
50 and 200 ng depending on the complexity. The reaction was performed in a 50 µl
volume using the Expand Long Template System (Roche) and 29 reaction cycles.
After the PCR all reactions were combined and the DNA purified with a PCR clean
up Kit (Qiagen). All samples were sequenced with the HiSeq 4000 (Illumina)
technology according to the standard protocols and with around 20 million single-
end reads per sample.
Reads were pre-processed, filtered for artefacts, and mapped to the reference
genome GRCh37 using BWA-MEM as described earlier36. After removing the
viewpoint fragment as well as 1.5 kb up- and downstream of the viewpoint the raw
read counts were normalized per million mapped reads (RPM) and a window of 10
fragments was chosen to smooth the profile.
Whole-genome sequencing. Cells were harvested and DNA was extracted using
the NucleoSpin Tissue kit (Macherey-Nagel GmbH & Co. KG, Düren, Germany).
Libraries for whole-genome sequencing were prepared with the NEBNext Ultra II
FS DNA Library Prep Kit for Illumina (New England BioLabs, Inc., Ipswich, MA).
Libraries were sequenced on a MGISEQ-2000 (NGP; MGI Tech Co. Ltd, Shenzhen,
China), HiSeq X (IMR-5/75, Kelly; Illumina, Inc., San Diego, CA), and NovaSeq
6000 (CHP-212; Illumina, Inc., San Diego, CA) with 2 × 150 bp paired-end reads.
Quality control, adapter trimming, alignment, duplicate removal as for ChIP-seq
data. Copy-number variation was called (Control-FREEC58 11.4 with default
parameters). Structural variants were called using SvABA59 (1.1.1) in germline
mode and discarding regions in a blacklist provided by SvABA (https://data.
broadinstitute.org/snowman/svaba_exclusions.bed).
Nanopore sequencing. Cells were harvested and high molecular weight DNA was
extracted using the MagAttract HMW DNA Kit (Qiagen N.V., Venlo, Nether-
lands). Size selection was performed to remove fragments <10 kilobases (kb) using
the Circulomics SRE kit (Circulomics Inc., Baltimore, MD). DNA content was
measured with a Qubit 3.0 Fluorometer (Thermo Fisher) and sample quality
control was performed using a 4200 TapeStation System (Agilent Technologies,
Inc., Santa Clara, CA). Libraries were prepared using the Ligation Sequencing Kit
(SQK-LSK109, Oxford Nanopore Technologies Ltd, Oxford, UK) and sequenced
on a R9.4.1 MinION flowcell (FLO-MIN106, Oxford Nanopore Technologies Ltd,
Oxford, UK). Quality control was performed using NanoPlot 1.0.0 (ref. 60). For the
NGP cell line, DNA was extracted with the NucleoSpin Tissue kit (Macherey-Nagel
GmbH & Co. KG, Düren, Germany) and libraries were prepared using the ONT
Rapid Kit (SQK-RBK004, Oxford Nanopore Technologies Ltd, Oxford, UK).
Guppy 2.3.7 (Oxford Nanopore Technologies Ltd, Oxford, UK) was used for
basecalling with default parameters. For de novo assembly, Flye 2.4.2 (ref. 61) was
run in metagenomics assembly mode on the unfiltered FASTQ files with an esti-
mated genome size of 1 Gb. Contigs were mapped back to hg19 using minimap2
2.16 (ref. 62) with parameter -ax asm5. Assembly results were visualized with
Bandage 0.8.1 (ref. 63) and Ribbon 1.0 (ref. 64). CpG methylation was called from
the unfiltered raw FAST5 files using Megalodon 0.1.0 (Oxford Nanopore Tech-
nologies Ltd, Oxford, UK). Motif signatures were derived with Homer (4.9.1)65
using the binomial test against nucleotide composition-matched background
sequences. CpG methylation composite profiles were created by averaging signal in
50 bp bins using computeMatrix in deepTools (3.3.0)48.
Fluorescence in situ hybridization. Cells were grown to 200,000 per well in six-
well plates and metaphase-arrested using Colcemid (20 µl/2 ml; Roche
#10295892001) for 30 min–3 h, trypsinized, centrifuged (200g/10 min), washed,
and pelleted. Five milliliters of 0.4% KCl (4 °C; Roth #6781.1) was added to the
pellet and incubated for 10 min. One milliliter KCl and 1 ml MeOH/acetic acid 3:1
(Roth #4627.2, #KK62.1) was added drop-wise. In all, 2/5/5 ml of MeOH/acetic
acid was added in between centrifugation steps (200g/10 min), respectively. Sus-
pension was dropped on a slide from a height of 40 cm. Slides were washed with
PBS (Gibco, #70011036) and digested for 10 min in 0.04% pepsin solution in 0.001
N HCl. Slides were washed in 0.5× SSC, dehydrated with 70%/80%/100% EtOH
(3 min each), and air-dried. Ten microliters of the probe (Vysis LSI N-MYC;
#07J72-001; Lot #472123; Abbott Laboratories, Abbott Park, IL) were added and
coverslips fixed on the slide. Slides were incubated at 75 °C for 10 min and at 37 °C
overnight. The coverslip was removed and the slide was washed in 0.4× SSC/0.3%
IGEPAL (CA-630, #18896; Sigma-Aldrich Inc.) for 3 min at 60 °C and 2× SSC/0.1%
IGEPAL for 3 min at RT. Five microliters DAPI (Vectashield, #H-1200, Vector)
was added. A coverslip was added and fixed with nail polish.
Enhancer calling. MYCN-expressing cell lines were defined as cell lines with size-
Factor normalized expression of 100 or above based. We identified enhancer
candidate regions in a ±500 kb window around MYCN. We focused on regions
with a H3K27ac peak in the majority of MYCN-expressing, non-MYCN-amplified
cell lines, i.e. three or more. If the gap between two such regions was less than 2 kb,
they were joined. These regions were then ranked by the maximum difference in
H3K27ac signal fold change between non-amplified, MYCN-expressing, and non-
expressing cell lines. We chose the five highest-ranking regions as candidate reg-
ulatory elements. Enhancer regions were screened for transcription factor-binding
sequences from the JASPAR2018 (ref. 50) and JASPAR2020 (ref. 66) database using
the TFBSTools 1.20.0 (ref. 51) function matchPWM with min.score= “85%”. CRC-
driven super-enhancers were defined as all regions with a LILY-defined super-
enhancer in MYCN-expressing, non-MYCN-amplified cell lines that overlapped
with a GATA3, HAND2, or PHOX2B peak in CLB-GA.
Analysis of neuroblastoma copy-number data. Public data were downloaded
from https://github.com/padpuydt/copynumber_HR_NB/ (ref. 27). Samples that were
described asMYCN-amplified in the metadata but did not showMYCN amplification
in the copy-number profile were excluded. In order to generate an aggregate copy-
number profile, the genome was binned in 10 kb bins and number of samples with
overlapping amplifications was counted per bin. Randomized copy-number profiles
were generated by randomly sampling one of the original copy-number profiles on
chromosome 2 and randomly shifting it such thatMYCN is still fully included within
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an amplified segment. For class I-specific shuffling, e4 had to be included as well; for
class II-specific shuffling, e4 was never included on the randomly shifted amplicon.
Empirical P values for significant co-amplification were derived by creating 10,000
randomized datasets with each amplicon randomly shifted and comparing the
observed co-amplification frequency to the distribution of co-amplification fre-
quencies in the randomized data. Empirical P values were always one-sided and
adjusted for multiple comparisons using the Benjamini–Hochberg procedure.
Analysis of medulloblastoma copy number and ChIP-seq data. Medullo-
blastoma Affymetrix SNP6 data (10 cell lines, 1087 patient samples) were down-
loaded from Gene Expression Omnibus (GSE37385)29 and processed using
rawcopy 1.1 (ref. 67) with default parameters. Segments with a log2 ratio ≥1.8 were
classified as amplifications. The genome was binned in 10 kb bins and the number
of samples with overlapping amplifications was counted per bin to generate
composite copy-number plots.
Medulloblastoma H3K27ac ChIP-seq BigWig files and super-enhancer regions
were downloaded from https://pecan.stjude.cloud/dataset/northcott (ref. 30). The
medulloblastoma subgroup-wise average H3K27ac signal was computed in 1 kb bins.
Amplicon reconstruction. All unfiltered SvABA structural variant calls were fil-
tered to exclude regions from the ENCODE blacklist68 and small rearrangements
of 1 kb or less. As we were only aiming at the rearrangements common to all
amplicons, we only considered breakpoints with more than 50 variant-support
reads (“allele depth”). gGnome69 was used to represent these data as a genome
graph with nodes being breakpoint-free genomic intervals and edges being rear-
rangements (“alternate edge”) or connections in the reference genomes (“reference
edge”). We considered only nodes with high copy number, i.e. with a mean whole-
genome sequencing coverage of at least 10-fold the median coverage of chromo-
some 2. Then, reference edges were removed if its corresponding alternate edge was
among the 25% highest allele-depth edges. The resulting graph was then searched
for the circular, MYCN-containing walk that included the highest number of nodes
without using any node twice. We used gTrack (https://github.com/mskilab/
gTrack) for visualization. For custom Hi-C maps of reconstructed amplicon
sequences of CHP-212 and IMR-5-75, respectively, the corresponding regions from
chromosome 2 were copied, ordered, oriented, and compiled according to the
results from the amplicon reconstruction and added to the reference genome.
Additionally, these copied regions were masked with “N” at the original locations
on chromosome 2 to allow a proper mapping of reads to the amplicon sequence.
The contribution of Hi-C di-tags from these regions on chromosome 2 to the
amplicon Hi-C map is expected be minor, because the copy number of amplicons
is much higher than the number of wild-type alleles.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Sequencing data generated for this study are available at the Sequence Read Archive
under accession PRJNA622577. Copy-number data for high-risk neuroblastoma were
downloaded from https://github.com/padpuydt/copynumber_HR_NB/ (ref. 27). Public
data supporting the findings of this manuscript were downloaded from the Gene
Expression Omnibus under accessions GSE90683, GSE80152, GSE24447, GSE37385,
GSE18927, and GSE28874 and from ArrayExpress under accession E-MTAB-6570.
Medulloblastoma ChIP-seq data were downloaded from https://pecan.stjude.cloud/
dataset/northcott. BigWig und narrowPeak files can be downloaded from https://data.
cyverse.org/dav-anon/iplant/home/konstantin/helmsaueretal/. An accompanying UCSC
genome browser track hub is provided for ChIP-seq and ATAC-seq data visualization
(https://de.cyverse.org/dl/d/27AA17DA-F24C-4BF4-904C-62B539A47DCC/hub.txt). All
other data are available from the corresponding authors upon reasonable request. Source
data are provided with this paper.
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